This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
XELJANZ® (tofacitinib citrate) Prescribing Information and Maxtrex (methotrexate) Prescribing Information. Adverse event reporting can be found at the bottom of the page.
Tofacitinib should only be used if no suitable treatment alternatives are available in patients:
These risks are considered class effects and relevant across all approved indications of JAKi in inflammatory and dermatologic diseases.
GRAPPA; the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and is a global association of more than 500 rheumatologists, dermatologists, and patient research partners.
The GRAPPA treatment recommendations are developed to assist clinicians in managing patients with PsA. To remain clinically relevant, these recommendations must be dynamic, and so require regular updates to include new evidence. An update of the GRAPPA recommendations for PsA, last completed in 2015, was required to include novel therapeutic approaches in the field. Updates are developed by utilising the most current approaches to guideline formation and ethical standards, analysing the best available evidence, and involving diverse stakeholders in the process. The result is relevant, patient centric treatment recommendations. The goal of this update was the same as in 2009: to develop treatment recommendations based on the best available evidence for the management of patients with PsA. See a short summary video outlining the updates immediately below or watch the full interactive version later on this page.
Watch a 4 minute video summary of the recently published GRAPPA treatment recommendations from 2021.
To watch a 10 minute video infographic recording of the recently published GRAPPA treatment recommendations from 2021, click below.
If you are a Rheumatologist and would like to hear more about the use of Xeljanz in Rheumatoid Arthritis click below.
If you are a Dermatologist and would like to hear more about Pfizer's therapy for Atopic Dermatitis click below.
Prescribing Information
Enbrel® (etanercept) Prescribing Information
Professor Laura Coates M.B.Ch.B. is the Co-lead of the GRAPPA recommendations and is an Associate Professor and NIHR Clinician Scientist at the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford as well as an Honorary Consultant Rheumatologist at Oxford University Hospital NHS Trust.
Take a look at the Xeljanz PsA clinical studies by clicking below.
Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.
PP-PFE-GBR-2809. March 2021
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024